首页> 外文期刊>Journal of Medicinal Chemistry >Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders
【24h】

Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders

机译:含WD重复序列蛋白5(WDR5)降解剂的设计、合成与评价

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Histone H3K4 methylation serves as a post-translational hallmark of actively transcribed genes and is introduced by histone methyltransferase (HMT) and its regulatory scaffolding proteins. One of these is the WD-repeat-containing protein 5 (WDR5) that has also been associated with controlling long noncoding RNAs and transcription factors including MYC. The wide influence of dysfunctional HMT complexes and the typically upregulated MYC levels in diverse tumor types suggested WDR5 as an attractive drug target. Indeed, protein-protein interface inhibitors for two protein interaction interfaces on WDR5 have been developed. While such compounds only inhibit a subset of WDR5 interactions, chemically induced proteasomal degradation of WDR5 might represent an elegant way to target all oncogenic functions. This study presents the design, synthesis, and evaluation of two diverse WDR5 degrader series based on two WIN site binding scaffolds and shows that linker nature and length strongly influence degradation efficacy.
机译:组蛋白 H3K4 甲基化是活跃转录基因的翻译后标志,由组蛋白甲基转移酶 (HMT) 及其调节支架蛋白引入。其中之一是含 WD 重复序列的蛋白 5 (WDR5),它也与控制长链非编码 RNA 和转录因子(包括 MYC)有关。功能失调的HMT复合物的广泛影响和不同肿瘤类型中通常上调的MYC水平表明WDR5是一个有吸引力的药物靶点。事实上,已经开发了用于WDR5上两个蛋白质相互作用界面的蛋白质-蛋白质界面抑制剂。虽然这些化合物仅抑制WDR5相互作用的一个子集,但化学诱导的WDR5蛋白酶体降解可能代表了靶向所有致癌功能的一种优雅方法。本研究介绍了基于两个WIN位点结合支架的两种不同WDR5降解剂系列的设计、合成和评估,并表明连接子的性质和长度对降解效果有很大影响。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号